跳至主要内容
临床试验/NCT00842374
NCT00842374已完成不适用

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

Minneapolis Heart Institute Foundation1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2008年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
1
主要终点
Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality

研究概览

简要总结

This is a registry of patients with non ST segment elevation Myocardial Infarction (heart attack) and/or unstable acute coronary artery syndrome treated with a standardized protocol including Bivalirudin.

Data will be collected on diagnosis, treatment and outcomes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chest pain or symptoms believed to be an anginal equivalent and representing myocardial ischemia, lasting at least 10 minutes within the past 24 hours
  • Having any one of the following:
  • Ischemic changes on ECG: ST depression >0.5 mm OR T wave inversion >2 mm
  • Positive cardiac markers
  • New onset CHF presumed secondary to ischemia
  • Pulmonary edema
  • Known coronary artery disease with typical symptoms
  • Hemodynamic instability
  • Sustained ventricular tachycardia

排除标准

  • For the purpose of the SSDI, patients will be excluded if we are unable to obtain their Social Security Number.

结局指标

主要结局

Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality

时间窗: 30 days

次要结局

  • Rehospitalization for ACS(30 days)
  • Major Bleeding(in hospital and at 30 days)
  • All cause mortality(30 days, one year and up to 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验